Among the alterations with lower levels of targetability in NSCLC, but worthy of special attention, are ESCAT IIB level: ERBB2 (amplifications or hotspot mutations); ESCAT IIIA: BRCA1/2 and PIK3CA (low frequency, approximately 1.2%); and NRG 1-ESCAT fusion IIIB [23]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.